Stock 1167 JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Jacobio Pharmaceuticals Group Co., Ltd.

Equities

1167

KYG4987A1094

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:10 21/05/2024 BST 		5-day change 1st Jan Change
1.88 HKD -4.08% Intraday chart for Jacobio Pharmaceuticals Group Co., Ltd. +4.44% -48.07%
05-13 Jacobio Pharmaceuticals Reports Approval for Phase 3 Trial for Combination Therapy Between Glecirasib and Cetuximab MT
05-10 Jacobio Pharmaceuticals Group Co., Ltd. Receives Approval of Registrational Phase III Clinical Trial of Glecirasib (Jab-21822) and Epidermal Growth Factor Receptor Inhibitor Erbitux in Patients with Colorectal Cancer CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 9,053 9,115 3,563 2,605 1,380 - -
Enterprise Value (EV) 1 7,436 7,584 2,413 1,594 917.4 677.1 1,100
P/E ratio - -29.5 x -9.43 x - - - -
Yield - - - - - - -
Capitalization / Revenue 18.6 x 59.6 x 37.2 x 41 x - 22.9 x 6.68 x
EV / Revenue 15.3 x 49.6 x 25.2 x 25.1 x - 11.2 x 5.33 x
EV / EBITDA 35.3 x -25.1 x -5.22 x -4.08 x -2.03 x -1.33 x -2.7 x
EV / FCF - -47,809,415 x - - - - -
FCF Yield - -0% - - - - -
Price to Book - 5.39 x 2.78 x - - - -
Nbr of stocks (in thousands) 759,654 771,462 771,462 791,755 791,755 - -
Reference price 2 11.92 11.81 4.619 3.290 1.743 1.743 1.743
Announcement Date 26/03/21 22/03/22 22/03/23 28/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 486 152.8 95.75 63.52 - 60.31 206.6
EBITDA 1 210.8 -301.8 -461.8 -390.7 -452.7 -508 -408.2
EBIT 1 202.4 -312.6 -475.6 -415.7 -462.2 -517.3 -417.3
Operating Margin 41.64% -204.56% -496.69% -654.49% - -857.66% -202.03%
Earnings before Tax (EBT) - -301.2 -371.9 - - - -
Net income - -301.2 -371.9 - - - -
Net margin - -197.1% -388.38% - - - -
EPS - -0.4000 -0.4900 - - - -
Free Cash Flow - -158.6 - - - - -
FCF margin - -103.81% - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share 2 - - - - - - -
Announcement Date 26/03/21 22/03/22 22/03/23 28/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2020 S2 2021 S1 2021 S2 2022 S1 2022 S2 2023 S1 2023 S2 2024 S1 2024 S2
Net sales 1 486 57.69 95.12 54.69 41.06 40.34 23.18 - -
EBITDA - - - - - - - - -
EBIT 1 - -135.6 -177 -190.5 -285 -220.1 -195.7 -213.3 -248.9
Operating Margin - -235.11% -186.03% -348.41% -694.19% -545.59% -843.94% - -
Earnings before Tax (EBT) - - - - - - - - -
Net income - - - -127.8 - - - - -
Net margin - - - -233.74% - - - - -
EPS - - - -0.1700 - - - - -
Dividend per Share - - - - - - - - -
Announcement Date 26/03/21 24/09/21 22/03/22 23/08/22 22/03/23 30/08/23 28/03/24 - -
1CNY in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - -
Net Cash position 1 1,617 1,531 1,151 1,012 462 703 280
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - -159 - - - - -
ROE (net income / shareholders' equity) - -17.6% -25.5% - - - -
ROA (Net income/ Total Assets) - -16.8% -22.6% - - - -
Assets - 1,795 1,648 - - - -
Book Value Per Share - 2.190 1.660 - - - -
Cash Flow per Share - -0.2000 - - - - -
Capex - 11.1 - - - - -
Capex / Sales - 7.29% - - - - -
Announcement Date 26/03/21 22/03/22 22/03/23 28/03/24 - - -
1CNY in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
1.743 CNY
Average target price
3.954 CNY
Spread / Average Target
+126.88%
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
JACOBIO PHARMACEUTICALS GROUP CO., LTD. Stock Jacobio Pharmaceuticals Group Co., Ltd.
-48.07% 199M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+7.77% 115B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.93% 107B
BIONTECH SE Stock BioNTech SE
-13.18% 22.31B
ARGENX SE Stock argenx SE
-3.99% 21.6B
BEIGENE, LTD. Stock BeiGene, Ltd.
-6.63% 18.23B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.93% 17.62B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.96% 14.26B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+32.70% 12.37B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-28.37% 8.28B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 1167 Stock
  4. Financials Jacobio Pharmaceuticals Group Co., Ltd.